News

Eli Lilly’s early-stage obesity drug causes up to 11% of weight loss in three months
Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial
Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...